Oppenheimer Maintains Their Buy Rating on Millendo Therapeutics (MLND)

By Carrie Williams

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Millendo Therapeutics (MLNDResearch Report). The company’s shares closed last Monday at $6.10, close to its 52-week low of $4.56.

According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -14.8% and a 28.3% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Millendo Therapeutics is a Strong Buy with an average price target of $27.67.

See today’s analyst top recommended stocks >>

Based on Millendo Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $12.7 million. In comparison, last year the company had a GAAP net loss of $5.68 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Millendo Therapeutics, Inc. engages in the development of treatments for orphan endocrine diseases. Its product pipeline includes Livoletide (AZP-531) for the treatment of Prader-Willi syndrome; Nevanimibe for classic congenital adrenal hyperplasia; and Neurokinin 3 receptor for vasomotor symptoms.